Urabrelimab is a humanized anti-CD47 monoclonal antibody. Urabrelimab binds to CD47 and inhibits CD47-SIRP_ interaction. Urabrelimab exerts antitumor activity in vitro through both phagocytosis and cell death in a manner dependent on the activating Fc-gamma receptor (Fc_R), CD32a.